Enabling continuity of care while allowing patients to stay home
SAN CARLOS, Calif., March 19, 2020 /PRNewswire/ — Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced expanded access to its virtual ordering platforms and remote testing capabilities across its reproductive, oncology and organ transplant businesses.
Natera’s tests inform critical medical decisions, and the need to carry out these essential tests does not stop, even in these challenging times. To meet this demand, testing can be fulfilled remotely, delivered at the push of a button with virtual ordering and remote blood draws in the comfort and safety of a patient’s home. "We are focused on helping physicians ensure continuity of essential medical care, while protecting the safety and well-being of our patients," said Steve Chapman, CEO.
The remote functionality is fulfilled through Natera’s online platforms and a nationwide mobile blood draw network that performed roughly 10,000 in-home draws in 2019.
Natera provides essential medical services for thousands of patients every day, and our laboratories continue to operate at high throughput levels. Stringent health and safety precautions have been implemented in all of our facilities to ensure the continuity of testing operations. These include daily health checks for lab staff and a work-from-home policy for all non-lab employees.
Natera is a global leader in cell-free DNA testing. The mission of the company is to change the management of disease worldwide with a focus on reproductive health, oncology, and organ transplantation. Natera operates an ISO 13485-certified and CAP-accredited laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, Calif. It offers proprietary genetic testing services to inform obstetricians, transplant physicians, oncologists, and cancer researchers, including biopharmaceutical companies, and genetic laboratories through its cloud-based software platform. For more information, visit natera.com. Follow Natera on LinkedIn.
All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera’s expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to our efforts to develop and commercialize new product offerings, our ability to successfully increase demand for and grow revenues for our product offerings, or of our expectations of the benefits of our screening tests and product offerings to patients, providers and payers. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera’s recent filings on Forms 10-K and 10-Q and in other filings Natera makes with the SEC from time to time. These documents are available at www.natera.com/investors and www.sec.gov.
Investor Relations: Mike Brophy, CFO, Natera, Inc., 650-249-9090
Media: Paul Greenland, VP of Corporate Marketing, firstname.lastname@example.org
SOURCE Natera, Inc.